FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238038517> ?p ?o ?g. }

• W4238038517 endingPage "633" @default.
• W4238038517 startingPage "632" @default.
• W4238038517 abstract "Cervical intraepithelial neoplasia (CIN) is a common disease among women of reproductive age. High-grade CIN lesions (CIN 2–3) are precancerous and can progress to cervical cancer. The most important risk factor for the development of CIN and progression to cervical cancer is persistent high-risk human papillomavirus (HPV) infection. The preferred treatment in most countries is surgical excision using conization. There is high need for a medical treatment alternative to surgical therapy for CIN 2–3 largely because of the risk of preterm birth and other long-term sequelae of cervical conization in future pregnancies. No medical therapy has been established in clinical practice for patients with CIN 2–3. In 2008, a study reported on the efficacy of imiquimod, a topical immune response modulator, against HPV-related vulvar intraepithelial neoplasia. Earlier this year, a randomized controlled trial found that combined use of imiquimod and conization did not improve CIN 2–3 recurrence rates compared with use of conization alone. However, the study had a number of design flaws. A major problem was the application of imiquimod only 5 times before surgery, an uncommon and short treatment regimen. The aim of the present randomized, double-blind, placebo-controlled phase 2 trial was to estimate the therapeutic efficacy of vaginal, self-applied imiquimod in women with high-risk HPV-positive CIN 2–3. Study subjects were 59 patients with untreated, histologically proven, high-risk, HPV-positive, and newly diagnosed CIN 2–3. Eligible women were randomized to receive either treatment with self-applied vaginal suppositories containing imiquimod or placebo for 16 weeks. The primary study outcome was efficacy, defined as histologic regression to CIN 1 or less following treatment. Secondary outcomes included complete histologic remission, HPV clearance, and treatment tolerability. A sample size of 24 patients per group was calculated to detect a 35% absolute increase in CIN 2–3 regression (imiquimod vs. placebo), assuming a 2-sided 5% significance level and a power of 80%. All patients tested positive for high-risk HPV at baseline. After 16 weeks of treatment, histologic regression to CIN 1 or less was achieved in 73% in the imiquimod group compared with 39% in the placebo group (P = 0.009). There was a higher complete histologic remission in the imiquimod group (47%) than in the placebo group (14%) (P = 0.008). Human papillomavirus clearance rates after treatment were 60% in the imiquimod group and 14% in the placebo group (P < 0.001). Complete remission rates among patients with HPV-16 infection were 47% in the imiquimod group and 0% in the placebo group (P = 0.003). Three of the 59 patients (5%), all within the placebo group, were found to have microinvasive cervical cancer after treatment. Topical imiquimod had no high-grade adverse effects; treatment was well tolerated. These findings suggest that vaginal imiquimod therapy is an efficacious, feasible, and well-tolerated medical treatment for patients with CIN 2–3." @default.
• W4238038517 created "2022-05-12" @default.
• W4238038517 creator A5014722961 @default.
• W4238038517 creator A5018390548 @default.
• W4238038517 creator A5019584888 @default.
• W4238038517 creator A5040146633 @default.
• W4238038517 creator A5040632107 @default.
• W4238038517 creator A5041520697 @default.
• W4238038517 creator A5045238374 @default.
• W4238038517 creator A5051069867 @default.
• W4238038517 creator A5067689684 @default.
• W4238038517 creator A5071381772 @default.
• W4238038517 date "2012-10-01" @default.
• W4238038517 modified "2023-10-18" @default.
• W4238038517 title "Treatment of Cervical Intraepithelial Neoplasia With Topical Imiquimod" @default.
• W4238038517 doi "https://doi.org/10.1097/ogx.0b013e31826f7c35" @default.
• W4238038517 hasPublicationYear "2012" @default.
• W4238038517 type Work @default.
• W4238038517 citedByCount "79" @default.
• W4238038517 countsByYear W42380385172012 @default.
• W4238038517 countsByYear W42380385172013 @default.
• W4238038517 countsByYear W42380385172014 @default.
• W4238038517 countsByYear W42380385172015 @default.
• W4238038517 countsByYear W42380385172016 @default.
• W4238038517 countsByYear W42380385172017 @default.
• W4238038517 countsByYear W42380385172018 @default.
• W4238038517 countsByYear W42380385172019 @default.
• W4238038517 countsByYear W42380385172020 @default.
• W4238038517 countsByYear W42380385172021 @default.
• W4238038517 countsByYear W42380385172022 @default.
• W4238038517 countsByYear W42380385172023 @default.
• W4238038517 crossrefType "journal-article" @default.
• W4238038517 hasAuthorship W4238038517A5014722961 @default.
• W4238038517 hasAuthorship W4238038517A5018390548 @default.
• W4238038517 hasAuthorship W4238038517A5019584888 @default.
• W4238038517 hasAuthorship W4238038517A5040146633 @default.
• W4238038517 hasAuthorship W4238038517A5040632107 @default.
• W4238038517 hasAuthorship W4238038517A5041520697 @default.
• W4238038517 hasAuthorship W4238038517A5045238374 @default.
• W4238038517 hasAuthorship W4238038517A5051069867 @default.
• W4238038517 hasAuthorship W4238038517A5067689684 @default.
• W4238038517 hasAuthorship W4238038517A5071381772 @default.
• W4238038517 hasConcept C121608353 @default.
• W4238038517 hasConcept C126322002 @default.
• W4238038517 hasConcept C131872663 @default.
• W4238038517 hasConcept C141071460 @default.
• W4238038517 hasConcept C142724271 @default.
• W4238038517 hasConcept C16005928 @default.
• W4238038517 hasConcept C168563851 @default.
• W4238038517 hasConcept C204787440 @default.
• W4238038517 hasConcept C27081682 @default.
• W4238038517 hasConcept C2777343196 @default.
• W4238038517 hasConcept C2778220009 @default.
• W4238038517 hasConcept C2778580637 @default.
• W4238038517 hasConcept C2779112978 @default.
• W4238038517 hasConcept C29456083 @default.
• W4238038517 hasConcept C71924100 @default.
• W4238038517 hasConceptScore W4238038517C121608353 @default.
• W4238038517 hasConceptScore W4238038517C126322002 @default.
• W4238038517 hasConceptScore W4238038517C131872663 @default.
• W4238038517 hasConceptScore W4238038517C141071460 @default.
• W4238038517 hasConceptScore W4238038517C142724271 @default.
• W4238038517 hasConceptScore W4238038517C16005928 @default.
• W4238038517 hasConceptScore W4238038517C168563851 @default.
• W4238038517 hasConceptScore W4238038517C204787440 @default.
• W4238038517 hasConceptScore W4238038517C27081682 @default.
• W4238038517 hasConceptScore W4238038517C2777343196 @default.
• W4238038517 hasConceptScore W4238038517C2778220009 @default.
• W4238038517 hasConceptScore W4238038517C2778580637 @default.
• W4238038517 hasConceptScore W4238038517C2779112978 @default.
• W4238038517 hasConceptScore W4238038517C29456083 @default.
• W4238038517 hasConceptScore W4238038517C71924100 @default.
• W4238038517 hasIssue "10" @default.
• W4238038517 hasLocation W42380385171 @default.
• W4238038517 hasOpenAccess W4238038517 @default.
• W4238038517 hasPrimaryLocation W42380385171 @default.
• W4238038517 hasRelatedWork W2128434532 @default.
• W4238038517 hasRelatedWork W2156484133 @default.
• W4238038517 hasRelatedWork W2347793649 @default.
• W4238038517 hasRelatedWork W2371239295 @default.
• W4238038517 hasRelatedWork W2384537481 @default.
• W4238038517 hasRelatedWork W2392142303 @default.
• W4238038517 hasRelatedWork W2396716305 @default.
• W4238038517 hasRelatedWork W2894266182 @default.
• W4238038517 hasRelatedWork W4308001219 @default.
• W4238038517 hasRelatedWork W2074393293 @default.
• W4238038517 hasVolume "67" @default.
• W4238038517 isParatext "false" @default.
• W4238038517 isRetracted "false" @default.
• W4238038517 workType "article" @default.